Abstract
To explore the potential use of IAI.3B isolated from ovarian cancer cells in gene therapy for ovarian cancer, we identified the promoter region of the IAI.3B gene and created a replication-selective adenovirus, AdE3-IAI.3B, driven by the promoter. The promoter activity of IAI.3B is preferentially expressed in ovarian cancer cells with negligible expression in squamous cell carcinoma and normal cells. We inserted the IAI.3B promoter into the E1A promoter region of adenovirus to make an oncolytic adenovirus specific for ovarian cancer therapy. This oncolytic adenovirus, AdE3-IAI.3B specifically replicated only in ovarian cancer cells but not in other cancer or normal cells. AdE3-IAI.3B expressed E1A protein only in ovarian cancer cells but not in other cancer cells or normal cells. AdE3- IAI.3B lysed ovarian cancer cells but not other cancer or normal cells. AdE3-IAI.3B completely suppressed the tumor growth of ovarian cancer but not that of squamous cell carcinoma. From these results, AdE3-IAI.3B might provide a potential for the development of ovarian cancer gene therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
